Adverse prognostic factor ID'd in operable breast cancer

Adverse prognostic factor ID'd in operable breast cancer
For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

(HealthDay)—For women with operable breast cancer, moderate immunohistochemical expression of human epidermal growth factor receptor (HER)-2 (2+) without amplification of HER-2 (HER-2 2+/HER-2) is an adverse prognostic factor, according to a study published online Sept. 4 in The Oncologist.

Valentina Rossi, M.D., from the Institute for Cancer Research and Treatment in Candiolo, Italy, and colleagues compared the clinical outcomes of 1,150 women (median age, 58 years) with operable breast cancer who were not receiving adjuvant . Patients were stratified according to a common HER-2 testing algorithm.

Of the women, 40 percent were considered HER-2 0+; 39 percent were HER-2 1+; 10 percent were HER-2 2+/HER-2; and 11 percent were HER-2+ (3+ or HER-2+) by fluorescence in situ hybridization. The researchers found that, on multivariate analysis, a HER-2 2+/HER-2 status correlated with worse disease-free survival, compared with a HER-2 0 or 1+ status. A HER-2 2+/HER-2 status showed a time-dependent effect on the probability of disease-free survival, with an initial advantage that lessened every year by a factor of 1.649, compared with a HER-2+ status.

"A HER-2 2+/HER-2status is an adverse prognostic factor in patients with operable ," the authors write. "Because of suggestions from randomized trials that the benefits of adjuvant trastuzumab may not be limited to patients with HER-2+ tumors, patients with a HER-2 2+/HER-2status are ideal candidates for studies testing this hypothesis."

One author disclosed financial ties to the pharmaceutical industry.

More information: Abstract
Full Text (subscription or payment may be required)

add to favorites email to friend print save as pdf

Related Stories

Recommended for you

Generation of tanners see spike in deadly melanoma

4 hours ago

(AP)—Stop sunbathing and using indoor tanning beds, the acting U.S. surgeon general warned in a report released Tuesday that cites an alarming 200 percent jump in deadly melanoma cases since 1973.

Penn team makes cancer glow to improve surgical outcomes

4 hours ago

The best way to cure most cases of cancer is to surgically remove the tumor. The Achilles heel of this approach, however, is that the surgeon may fail to extract the entire tumor, leading to a local recurrence.

Cancer: Tumors absorb sugar for mobility

16 hours ago

Cancer cells are gluttons. We have long known that they monopolize large amounts of sugar. More recently, it became clear that some tumor cells are also characterized by a series of features such as mobility or unlikeliness ...

User comments